{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:39:28Z","timestamp":1787071168871,"version":"build-2736575974"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context:<\/jats:title>\n                    <jats:p>The survival of patients diagnosed with osteosarcoma has not improved in the past three decades because of chemoresistance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim:<\/jats:title>\n                    <jats:p>This study aimed to improve the prognosis of patients with osteosarcoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Settings and Design<\/jats:title>\n                    <jats:p>From January 1, 2018, to June 30, 2019, a total of 14 patients with osteosarcoma were enrolled who underwent mini patient-derived xenograft (mini-PDX) assay in our hospital.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and Materials:<\/jats:title>\n                    <jats:p>We recruited 14 patients with osteosarcoma having acquirable lesions to establish PDX models and examine the sensitivity of nine drugs, including methotrexate (MTX), ifosfamide (IFO), epirubicin, and etoposide. Drug sensitivity was evaluated using the tumor relative proliferation rate (TRPR), and the patients\u2019 responses were assessed according to the RECIST 1.1 guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Statistical Analysis Used:<\/jats:title>\n                    <jats:p>The difference in TRPR was analyzed using a paired t-test, while progression-free survival (PFS) was analyzed using the Kaplan\u2013Meier method.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The mini-PDX results revealed that IFO had a lower tumor proliferation rate than MTX, indicating that IFO was more sensitive in patients with osteosarcoma (38.3% vs. 84.3%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.031). Thus, the regimen where IFO alternates with doxorubicin and cisplatin was recommended as adjuvant chemotherapy. MTX could replace IFO if the TRPR was better. Finally, 11 patients received adjuvant chemotherapy. A comparison of PFS revealed that sensitive patients with TRPR of &lt;40% had a better prognosis (9.4 months vs. 3.7 months,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.0324).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Chemotherapy based on mini-PDX can improve the survival of patients with osteosarcoma whose TRPR was &lt;40%, and that chemotherapy without MTX could be an alternative for osteosarcoma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_825_22","type":"journal-article","created":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T19:34:41Z","timestamp":1729539281000},"page":"71-77","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Predicting chemosensitivity based on mini patient-derived xenografts in osteosarcoma patients: A retrospective study"],"prefix":"10.4103","volume":"19","author":[{"given":"Zuoyao","family":"Long","sequence":"first","affiliation":[{"name":"Department of Orthopedics, Xijing Hospital, Air Force Medical University of PLA, Xi\u2019An, China"},{"name":"Department of Orthopedics, General Hospital of Northern Theater Command, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajie","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Xijing Hospital, Air Force Medical University of PLA, Xi\u2019An, China"},{"name":"Department of Clinical Oncology, Xijing Hospital, Air Force Medical University of PLA, Xi\u2019An, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghui","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Xijing Hospital, Air Force Medical University of PLA, Xi\u2019An, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanlei","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Institute of Orthopedics, China Railway Xi\u2019An Hospital of Genertec Universal Medical Group Company Limited, Xi\u2019An, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guojing","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Xijing Hospital, Air Force Medical University of PLA, Xi\u2019An, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Xijing Hospital, Air Force Medical University of PLA, Xi\u2019An, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangbi","family":"Xiang","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, General Hospital of Northern Theater Command, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailong","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, General Hospital of Northern Theater Command, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, General Hospital of Northern Theater Command, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Xijing Hospital, Air Force Medical University of PLA, Xi\u2019An, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,3,3]]},"reference":[{"key":"R1-20241021","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/MPH.0000000000001332","article-title":"Young adult with osteosarcoma of the mandible and the challenge in management:Review of the pediatric and adult literatures","volume":"41","author":"Kuo","year":"2019","journal-title":"J Pediatr Hematol Oncol"},{"key":"R2-20241021","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ocl.2015.08.022","article-title":"Update on survival in osteosarcoma","volume":"47","author":"Anderson","year":"2016","journal-title":"Orthop Clin North Am"},{"key":"R3-20241021","first-page":"213","article-title":"Pediatric malignant bone tumors:A review and update on current challenges, and emerging drug targets","volume":"46","author":"Jackson","year":"2016","journal-title":"Curr Prob Pediatr Adolesc Health Care"},{"key":"R4-20241021","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.4103\/jcrt.JCRT_1092_20","article-title":"Microsatellite instability-high colorectal cancer patient-derived xenograft models for cancer immunity research","volume":"17","author":"Suto","year":"2021","journal-title":"J Cancer Res Ther"},{"key":"R5-20241021","first-page":"54","article-title":"Personalized treatment based on mini patient-derived xenografts and WES\/RNA sequencing in a patient with metastatic duodenal adenocarcinoma","volume":"38","author":"Zhao","year":"2018","journal-title":"Cancer Commun (Loud)"},{"key":"R6-20241021","first-page":"60","article-title":"Characterization of drug responses of mini patient-derived xenografts in mice for predicting cancer patient clinical therapeutic response","volume":"38","author":"Zhang","year":"2018","journal-title":"Cancer Commun (Loud)"},{"key":"R7-20241021","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/bcpt.13059","article-title":"Basic &clinical pharmacology &toxicology policy for experimental and clinical studies","volume":"123","author":"Tveden-Nyborg","year":"2018","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"R8-20241021","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.bbrc.2017.11.121","article-title":"Long non-coding RNA LUCAT1 modulates methotrexate resistance in osteosarcoma via miR-200c\/ABCB1 axis","volume":"495","author":"Han","year":"2018","journal-title":"Biochem Bioph Res Commun"},{"key":"R9-20241021","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/BF03033741","article-title":"Human osteosarcoma xenografts and their sensitivity to chemotherapy","volume":"10","author":"Bruheim","year":"2004","journal-title":"Pathol Oncol Res"},{"key":"R10-20241021","first-page":"326","article-title":"Enhanced antitumor activity of epirubicin combined with cerulenin in osteosarcoma","volume":"5","author":"Liu","year":"2012","journal-title":"Mol Med Rep"},{"key":"R11-20241021","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.rvsc.2017.09.019","article-title":"Anti-tumour efficacy of etoposide alone and in combination with piroxicam against canine osteosarcoma in a xenograft model","volume":"113","author":"Ong","year":"2017","journal-title":"Res Vet Sci"},{"key":"R12-20241021","article-title":"Experimental Study on the Effect of Several Antitumor Drugs on Human Osteosarcoma in Nude Mice Animal Model","author":"Hu","year":"2014","journal-title":"Nanjing University"},{"key":"R13-20241021","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.bbrc.2018.09.105","article-title":"Synergistic effect of docetaxel combined with cisplatin on inhibiting human osteosarcoma in nude mice","volume":"505","author":"Tao","year":"2018","journal-title":"Biochem Bioph Res Commun"},{"key":"R14-20241021","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1038\/aps.2018.16","article-title":"Combined treatment with apatinib and docetaxel in A549 xenograft mice and its cellular pharmacokinetic basis","volume":"39","author":"Feng","year":"2018","journal-title":"Acta Pharmacol Sin"},{"key":"R15-20241021","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.3390\/cancers12113097","article-title":"Gemcitabine and rapamycin exhibit additive effect against osteosarcoma by targeting autophagy and apoptosis","volume":"12","author":"Ando","year":"2020","journal-title":"Cancers (Basel)"},{"key":"R16-20241021","first-page":"3904","article-title":"Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts","volume":"8","author":"Pratesi","year":"2002","journal-title":"Clin Cancer Res"},{"key":"R17-20241021","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13028-017-0341-9","article-title":"Comparative review of human and canine osteosarcoma:morphology, epidemiology, prognosis, treatment and genetics","volume":"59","author":"Simpson","year":"2017","journal-title":"Acta Vet Scand"},{"key":"R18-20241021","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1200\/JCO.2014.59.4895","article-title":"Osteosarcoma:Current treatment and a collaborative pathway to success","volume":"33","author":"Isakoff","year":"2015","journal-title":"J Clin Oncol"},{"key":"R19-20241021","doi-asserted-by":"crossref","first-page":"892","DOI":"10.4103\/jcrt.JCRT_461_17","article-title":"Expression of CD133 protein in osteosarcoma and its relationship with the clinicopathological features and prognosis","volume":"14","author":"Xie","year":"2018","journal-title":"J Cancer Res Ther"},{"key":"R20-20241021","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1177\/1778.19262","article-title":"Nonmetastatic osteosarcoma of the extremity Neoadjuvant chemotherapy with methotrexate, cisplatin, doxorubicin and ifosfamide. An Italian Sarcoma Group study (ISG\/osteosarcoma-Oss)","volume":"100","author":"Ferrari","year":"2014","journal-title":"Tumori"},{"key":"R21-20241021","doi-asserted-by":"crossref","first-page":"335","DOI":"10.4103\/jcrt.JCRT_11_20","article-title":"Correlation between the changes of serum COX 2, APE1, VEGF, TGF-b and TSGF levels and prognosis in patients with osteosarcoma before and after treatment","volume":"16","author":"Zhang","year":"2020","journal-title":"J Cancer Res Ther"},{"key":"R22-20241021","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s40272-014-0095-z","article-title":"The role of chemotherapy for metastatic, relapsed and refractory osteosarcoma","volume":"16","author":"Xiao","year":"2014","journal-title":"Paediatr Drugs"},{"key":"R23-20241021","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s10555-016-9653-x","article-title":"Patient-derived xenograft (PDX) models in basic and translational breast cancer research","volume":"35","author":"Dobrolecki","year":"2016","journal-title":"Cancer Metastasis Rev"},{"key":"R24-20241021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4143\/crt.2017.307","article-title":"The Generation and application of patient-derived xenograft model for cancer research","volume":"50","author":"Jung","year":"2018","journal-title":"Cancer Res Treat"},{"key":"R25-20241021","doi-asserted-by":"crossref","first-page":"889","DOI":"10.3390\/cells8080889","article-title":"Application of highly immunocompromised mice for the establishment of patient-derived xenograft (PDX) Models","volume":"8","author":"Okada","year":"2019","journal-title":"Cells"},{"key":"R26-20241021","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s40880-018-0318-8","article-title":"Guided chemotherapy based on patient-derived mini-xenograft models improves survival of gallbladder carcinoma patients","volume":"38","author":"Zhan","year":"2018","journal-title":"Cancer Communications"},{"key":"R27-20241021","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1200\/JCO.2014.60.0734","article-title":"Methotrexate, Doxorubicin, and Cisplatin (MAP) plus maintenance pegylated interferon Alfa-2b versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP:First results of the EURAMosteosarcoma-1 good response randomized controlled trial","volume":"33","author":"Bielack","year":"2015","journal-title":"J Clin Oncol"},{"key":"R28-20241021","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1007\/s00432-012-1214-2","article-title":"Clinical relations of methotrexate pharmacokinetics in the treatment for pediatric osteosarcoma","volume":"138","author":"Hegyi","year":"2012","journal-title":"J Cancer Res Clin Oncol"},{"key":"R29-20241021","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1365-2125.2011.04054.x","article-title":"High dose methotrexate chemotherapy:Pharmacokinetics, folate and toxicity in osteosarcoma patients","volume":"73","author":"Holmboe","year":"2012","journal-title":"Brit J Clin Pharmaco"},{"key":"R30-20241021","first-page":"2770","article-title":"Frontline treatment of localized osteosarcoma without methotrexate","volume":"117","author":"Daw","year":"2011","journal-title":"Cancer-Am Cancer Soc"},{"key":"R31-20241021","doi-asserted-by":"crossref","first-page":"e678","DOI":"10.3747\/co.21.1973","article-title":"Clinical analysis of osteosarcoma patients treated with high-dose methotrexate-free neoadjuvant chemotherapy","volume":"21","author":"Xu","year":"2014","journal-title":"Curr Oncol"},{"key":"R32-20241021","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejca.2017.08.013","article-title":"Outcomes in non-metastatic treatment naive extremity osteosarcoma patients treated with a novel non-high dosemethotrexate-based, dose-dense combination chemotherapy regimen 'OGS-12'","volume":"85","author":"Bajpai","year":"2017","journal-title":"Eur J Cancer"},{"key":"R33-20241021","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/ijc.32526","article-title":"Results of API\u2013AI based regimen in osteosarcoma adult patients included in the French osteosarcoma2006\/Sarcome-09 study","volume":"146","author":"Piperno Neumann","year":"2020","journal-title":"Int J Cancer"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_825_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:42:31Z","timestamp":1787067751000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_825_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_825_22","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"2022-04-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}